[68Ga]Ga-LNC1007 PET/CT 评估肾细胞癌:与 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT 的比较
这项前瞻性研究纳入 25 例经病理证实的肾细胞癌患者,比较 [68Ga]Ga-LNC1007 与 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT 对原发灶的检出率及参数差异,并探索 [68Ga]Ga-LNC1007 PET/CT 参数与病理特征的关系。结果显示 [68Ga]Ga-LNC1007 对原发灶检出率高于 2-[18F]FDG(13/17 vs 4/17,P=0.005),其 SUVmax 与 TBR 可有效区分 WHO/ISUP 分级和不良病理特征。
要点
- [68Ga]Ga-LNC1007 对原发灶检出率高于 2-[18F]FDG(13/17 vs 4/17,P=0.005)。
- [68Ga]Ga-LNC1007 的 SUVmax 与 TBR 可区分 WHO/ISUP 3-4 级与 1-2 级。
- [68Ga]Ga-LNC1007 的 SUVmax 与 TBR 可区分不良病理特征阳性与阴性。
核心结论
- [68Ga]Ga-LNC1007 是肾细胞癌显像中有前景的示踪剂,可有效识别肾细胞癌的侵袭性病理特征。
研究设计与样本
- 前瞻性研究,纳入 25 例经病理证实的肾细胞癌患者,比较 [68Ga]Ga-LNC1007 与 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT。
主要发现
- [68Ga]Ga-LNC1007 与 2-[18F]FDG 对原发灶检出率分别为 13/17 vs 4/17(P=0.005)。
- [68Ga]Ga-LNC1007 与 [68Ga]Ga-PSMA 对原发灶检出率分别为 9/11 vs 6/11(P=0.361)。
- [68Ga]Ga-LNC1007 较 2-[18F]FDG 的 SUVmax 为 6.6 vs 3.7(P=0.005)、SUVmean 为 4.1 vs 2.3(P=0.001)、TBR 为 2.6 vs 1.7(P=0.011)。
- [68Ga]Ga-LNC1007 较 [68Ga]Ga-PSMA 的 TBR 为 2.9 vs 0.5(P=0.003)、TBR-delay 为 2.8 vs 0.3(P=0.003)、GTV 为 84.1 vs 42.9(P=0.003)、TL-tracer 为 442.7 vs 235.8(P=0.008)。
- [68Ga]Ga-LNC1007 的 SUVmax 与 FAP 表达、整合素 αvβ3 表达及 FAP 与整合素 αvβ3 总表达呈正相关(r=0.577,P=0.006;r=0.701,P<0.001;r=0.702,P<0.001)。
关键数值与推荐
- [68Ga]Ga-LNC1007 的 SUVmax 区分 WHO/ISUP 3-4 级与 1-2 级:AUC 0.81,P=0.04。
- [68Ga]Ga-LNC1007 的 SUVmax 区分不良病理特征阳性与阴性:AUC 0.80,P=0.033。
- [68Ga]Ga-LNC1007 的 TBR 区分 WHO/ISUP 3-4 级与 1-2 级:AUC 0.84,P=0.026。
- [68Ga]Ga-LNC1007 的 TBR 区分不良病理特征阳性与阴性:AUC 0.85,P=0.014。
临床怎么用
- [68Ga]Ga-LNC1007 PET/CT 可有效识别肾细胞癌的侵袭性病理特征(作者结论)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the potential efficiency of [68Ga]Ga-LNC1007 with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT for detecting renal cell carcinoma (RCC) and to explore parameters derived from [68Ga]Ga-LNC1007 PET/CT for discriminating pathological characteristics in RCC. METHODS: Twenty-five RCC patients confirmed by pathology were enrolled in this prospective study. The maximum standardized uptake value (SUVmax), mean SUV (SUVmean), gross tumor volume (GTV) and total lesion-tracer (TL-tracer) of lesions were calculated from the corresponding PET/CT images. Pathological characteristics included World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade and adverse pathological features (tumor necrosis or sarcomatoid or rhabdoid feature). RESULTS: [68Ga]Ga-LNC1007 PET/CT showed a higher detection rate for primary lesions than 2-[18F]FDG and [68Ga]Ga-PSMA (LNC1007 vs. FDG: 13/17 vs. 4/17, P = 0.005; LNC1007 vs. PSMA: 9/11 vs. 6/11, P = 0.361). [68Ga]Ga-LNC1007 PET/CT showed higher SUVmax (6.6 vs. 3.7, P = 0.005), SUVmean (4.1 vs. 2.3, P = 0.001) and TBR (2.6 vs. 1.7, P = 0.011) compared with 2-[18F]FDG PET/CT, and it also showed higher TBR (2.9 vs. 0.5, P = 0.003), TBR-delay (2.8 vs. 0.3, P = 0.003), GTV (84.1 vs. 42.9, P = 0.003) and TL-tracer (442.7 vs. 235.8, P = 0.008) compared with [68Ga]Ga-PSMA PET/CT. SUVmax and TBR derived from [68Ga]Ga-LNC1007 PET/CT could effectively differentiate WHO/ISUP grade (3-4 vs. 1-2) and adverse pathological features (positive vs. negative) (SUVmax: AUC 0.81, P = 0.04; AUC 0.80, P = 0.033; TBR: AUC 0.84, P = 0.026; AUC 0.85, P = 0.014). The SUVmax was positively correlated with the FAP expression, integrin αvβ3 expression and the total expression of FAP and integrin αvβ3 (r = 0.577, P = 0.006, r = 0.701, P < 0.001, and r = 0.702, P < 0.001, respectively). CONCLUSION: [68Ga]Ga-LNC1007 is a promising tracer for RCC imaging and can effectively identify aggressive pathological characteristics of RCC.
引用
- Lin R, Wang C, Chen S, et al. [68Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2023. PMID: 37728667. doi:10.1007/s00259-023-06436-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。